Latest Headlines

Latest Headlines

Cerecor raises $26M in a downsized IPO to fund its depression pipeline

Baltimore biotech Cerecor raised $26 million in an IPO to bankroll its work on treatments for depression, issuing warrants to bring in the cash it needs.

Cerecor picks up a Lilly antidepressant with ambitions in addiction

Cerecor acquired the rights to an Eli Lilly antidepressant, planning to take the drug into Phase II as a treatment for addictive disorders. 

Cerecor raises $16M for PhII study of 'Special K' depression remedy

Baltimore-based Cerecor has gathered up the first half of a $33 million B round, with plans to devote much of that money to a midstage development program for an experimental depression therapy recently punted by a restructuring Merck.

Biotech startup bags $7M stake needed to in-license PhII Merck anti-depressant

A biotech with close ties to Johns Hopkins has snagged an added $6.8 million in backing, which will be used to in-license an antidepressant out of the Merck pipeline and prep it for a Phase II study.

Biotech vets back $22M A round for neuroscience startup

The former CEO of Alba Therapeutics, Blake Paterson, has put together a $22 million A round to launch his new biotech in Baltimore.